跳至主要内容
临床试验/NCT02918786
NCT02918786Unknown不适用

The Efficacy of the Whisperflow CPAP System Versus High Flow Nasal Cannula Oxygen Therapy in Patients at High Risk for Postextubation Failure

Ramathibodi Hospital2 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2016年2月最近更新:
适应症

试验速览

阶段
不适用
入组人数
140
试验地点
2
主要终点
Reintubation rate

研究概览

简要总结

The purpose of this study is to compare the effect of continuous positive airway pressure (CPAP) delivered by the variable generator WhisperFlow System with high flow nasal cannula oxygen therapy in mechanically ventilated patient who are at risk for postextubation failure.

详细描述

Postextubation respiratory failure is not an uncommon condition after discontinuation of mechanical ventilation. Subsequently reintubation and mechanical ventilation for postextubation respiratory failure may lead to increasing of hospital morbidity and mortality and and prolonging intensive care and hospital stay. Several studies have demonstrated the efficacy of non-invasive ventilation to prevent the postextubation failure in patients with high risk for extubation failure.

The variable generator whisper flow system ((Philips Respironics, Murrysville, PA, USA) is the one of widely used continuous positive airway pressure(CPAP) device in UK. This device employs an oxygen-driven venturi to entrain air and generates high fresh gas flow up to 140 liter per minute. The oxygen/air mixture enters the breathing circuit and exits through a threshold resistor namely CPAP valve. Whisperflow is able to provide the flow into the breathing system via oronasal mask which exceeds the peak inspiratory flow rate of the patient and may improve work of breathing as well as gas exchange. In daily clinical practice, the investigators apply this device with humidifier in patients with weaning difficulty and patients who are at risk for postextubation failure.

High-flow nasal oxygen therapy(HFNO) is a device which heated and humidified oxygen is distributed to the nose at high flow rates. With the high flow rate (up to 60 Liter per minute), it generates low level of positive airway pressure. Physiological benefits of HFNO comprises decreasing of the dead space, work of breathing and the low level of positive airway pressure associated with better lung recruitment. Furthermore, the fraction of inspired oxygen can be adjusted and measured by changing the fraction of oxygen in the driving gas.

In the present randomized, controlled trial, the investigators will compare two devices for oxygen therapy, with low levels of continuous positive airway pressure, nasal high-flow oxygen therapy and CPAP of 5 cmH2O delivered by the variable generator WhisperFlow System with oronasal mask , in critically ill patients who are at risk for postextubation failure. The investigators hypothesize that nasal high-flow is superior to CPAP the in terms of reintubation rate.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Mechanical ventilation > 48 hours and
  • high risk for extubation failure namely , congestive heart failure, ineffective cough and excessive tracheobronchial secretions, more than one failure of a weaning trial, more than one co-morbid condition, patients who had hypercapnia, and upper airway obstruction without immediately required intubation

排除标准

  • age<18 years
  • pregnancy
  • tracheostomy
  • uncontrolled cardiac ischemia or arrhythmias
  • unstable hemodynamic status
  • documented swallowing problem
  • documented cervical spine injury
  • Facial anatomical abnormalities interfering with the mask fit
  • agitated or uncooperative state
  • lack of informed consent

结局指标

主要结局

Reintubation rate

时间窗: 48 hours

Number of participants who required reintubation within 48 hours after extubation

次要结局

  • post extubation respiratory failure(48 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Pongdhep Theerawit

Assistant Professor

Ramathibodi Hospital

研究点 (2)

Loading locations...

相似试验

The Efficacy of the Whisperflow CPAP System Versus... | 临床试验